GlassScriptPhysician profile
William T Tsai
NPI 1285620443
$6,373.38
in general payments reported to CMS, 2019-2025
39 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $1,187 · 2021: $980 · 2022: $543 · 2023: $641 · 2024: $1,291 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $903.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $674.30 | 2019-2025 | |
| Lilly USA, LLC | $617.59 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $512.56 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $486.75 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.98 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $338.37 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $298.42 | 2019-2024 | Veozah |
| Amgen INC. | $292.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Inari Medical, INC. | $176.73 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $163.48 | 2021-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $144.01 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $141.33 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Teva Pharmaceuticals USA, INC. | $132.91 | 2022-2024 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.09 | 2021-2025 | Xifaxan |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $117.03 | 2023-2024 | Rexulti |
| Shield Therapeutics INC | $89.33 | 2022-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $82.16 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $81.75 | 2020-2021 | |
| Exact Sciences Corporation | $80.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $72.56 | 2019 | |
| Glaxosmithkline, LLC. | $55.73 | 2019-2023 | Shingrix |
| Sumitomo Pharma America, INC. | $39.23 | 2024 | Gemtesa |
| Corcept Therapeutics | $36.66 | 2025 | Korlym |
| Mannkind Corporation | $33.80 | 2019 | |
| Eisai INC. | $32.79 | 2021 | |
| Edwards Lifesciences Corporation | $27.87 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Avanos Medical | $27.48 | 2023 | On-Q* Pump and Accessories |
| Hologic Sales and Service, LLC | $27.26 | 2024 | Aptima |
| Insmed, INC. | $24.92 | 2024 | Arikayce |
| Biohaven Pharmaceuticals, INC. | $24.85 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.69 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $24.39 | 2022 | |
| Allergan, INC. | $22.70 | 2020 | |
| Hikma Pharmaceuticals USA | $21.81 | 2024 | Kloxxado |
| Abbvie INC. | $18.07 | 2025 | |
| Lundbeck LLC | $18.03 | 2024 | Rexulti |
| Mdd US Operations, LLC | $17.78 | 2023 | Apokyn |
| Bard Peripheral Vascular, INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.